Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. Geneva: World Health Organization; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542796/.
Gauthier S, Rosa-Neto P, Morais JA, & Webster C. 2021. World Alzheimer Report 2021: Journey through the diagnosis of dementia. London: Alzheimer’s Disease International.
De Strooper B. The cellular phase of Alzheimer’s disease. Cell. 2016;164(4):603–15. https://doi.org/10.1016/j.cell.2015.12.056.
Article CAS PubMed Google Scholar
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. The Lancet. 2021;397(10284):1577–90. https://doi.org/10.1016/s0140-6736(20)32205-4.
Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group. Lancet Neurol. 2021;20(6):484–96. https://doi.org/10.1016/s1474-4422(21)00066-1.
Article CAS PubMed PubMed Central Google Scholar
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. https://doi.org/10.1016/j.jalz.2018.02.018.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer’s disease. Neurology. 1984;34(7):939–44. https://doi.org/10.1212/wnl.34.7.939.
Article CAS PubMed Google Scholar
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. https://doi.org/10.1016/j.jalz.2011.03.005.
Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275–83. https://doi.org/10.1016/j.neurobiolaging.2010.04.007.
Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313(19):1939. https://doi.org/10.1001/jama.2015.4669.
Article PubMed PubMed Central Google Scholar
Morris GP, Clark IA, Vissel B. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathol. 2018;136(5):663–89. https://doi.org/10.1007/s00401-018-1918-8.
Article CAS PubMed PubMed Central Google Scholar
Van Der Flier WM, Scheltens P. The ATN framework—moving preclinical Alzheimer disease to clinical relevance. JAMA Neurology. 2022;79(10):968. https://doi.org/10.1001/jamaneurol.2022.2967.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8. https://doi.org/10.1001/archneur.56.3.303.
Article CAS PubMed Google Scholar
Grøntvedt GR, Lauridsen C, Berge G, et al. The amyloid, tau, and neurodegeneration (A/T/N) classification applied to a clinical research cohort with long-term follow-up. J Alzheimers Dis. 2020;74(3):829–37. https://doi.org/10.3233/jad-191227.
Article PubMed PubMed Central Google Scholar
Balasa M, Sánchez-Valle R, Antonell A, et al. Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. J Alzheimer’s Di. 2014;40(4):919–27. https://doi.org/10.3233/JAD-132195.
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 2015;313(19):1924–38. https://doi.org/10.1001/jama.2015.4668.
Article PubMed PubMed Central Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021: n71. https://doi.org/10.1136/bmj.n71.
Weiner MW. Alzheimer’s disease neuroimaging initiative. Available from: https://adni.loni.usc.edu/.
Aydin O, Yassikaya MY. Validity and reliability analysis of the plotdigitizer software program for data extraction from single-case graphs. Perspect Behav Sci. 2022;45(1):239–57. https://doi.org/10.1007/s40614-021-00284-0.
Huwaldt, J. A., & Steinhorst, S. (2020). Plot digitizer 2.6.9.PlotDigitizer-Software. http://plotdigitizer.sourceforge.net/.
Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal Fluid Aβ42/40 Corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis. 2017;55(2):813–22. https://doi.org/10.3233/jad-160722.
Article CAS PubMed Google Scholar
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.
Robins J, Greenland S, Breslow NE. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am J Epidemiol. 1986;124(5):719–23. https://doi.org/10.1093/oxfordjournals.aje.a114447.
Article CAS PubMed Google Scholar
Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Stat Methods Med Res. 2001;10(6):375–92. https://doi.org/10.1177/096228020101000602.
Article CAS PubMed Google Scholar
Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010;1(2):112–25. https://doi.org/10.1002/jrsm.11.
Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6. https://doi.org/10.7326/0003-4819-158-4-201302190-00009.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Jama. 2006;295(6):676–80. https://doi.org/10.1001/jama.295.6.676.
Article CAS PubMed Google Scholar
Kemppainen NM, Scheinin NM, Koivunen J, et al. Five-year follow-up of 11C-PIB uptake in Alzheimer’s disease and MCI. Eur J Nucl Med Mol Imaging. 2014;41(2):283–9. https://doi.org/10.1007/s00259-013-2562-0.
Article CAS PubMed Google Scholar
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98–106. https://doi.org/10.1001/archgenpsychiatry.2011.155.
Article CAS PubMed Google Scholar
Forlenza OV, Radanovic M, Talib LL, et al. Cerebrospinal fluid biomarkers in Alzheimer’s disease: diagnostic accuracy and prediction of dementia. Alzheimers Dement (Amst). 2015;1(4):455–63. https://doi.org/10.1016/j.dadm.2015.09.003.
Article PubMed PubMed Central Google Scholar
Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging. 2009;30(2):165–73. https://doi.org/10.1016/j.neurobiolaging.2007.06.009.
Article CAS PubMed Google Scholar
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94. https://doi.org/10.1111/j.1365-2796.2004.01388.x.
Article CAS PubMed Google Scholar
Arruda F, Rosselli M, Mejia Kurasz A, et al. Stability in cognitive classification as a function of severity of impairment and ethnicity: a longitudinal analysis. Article in Press. Appl Neuropsychol Adult. 2023:1-14. https://doi.org/10.1080/23279095.2023.2222861.
Baldeiras I, Silva-Spínola A, Lima M, et al. Alzheimer’s disease diagnosis based on the amyloid, tau, and neurodegeneration scheme (ATN) in a real-life multicenter cohort of general neurological centers. J Alzheimer’s Dis. 2022;90(1):419–32. https://doi.org/10.3233/JAD-220587.
Bos I, Verhey FR, Ramakers I, et al. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimers Res Ther. 2017;9(1):101. https://doi.org/10.1186/s13195-017-0328-9.
Article CAS PubMed PubMed Central Google Scholar
Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in Mild cognitive impairment predict heterogeneity of progression to dementia. Neuroimage Clin. 2015;7:187–94. https://doi.org/10.1016/j.nicl.2014.12.004.
de Wilde A, Reimand J, Teunissen CE, et al. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther. 2019;11(1):78. https://doi.org/10.1186/s13195-019-0532-x.
Article CAS PubMed PubMed Central Google Scholar
Eckerström C, Svensson J, Kettunen P, Jonsson M, Eckerström M. Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimers Dement (Amst). 2021;13(1): e12031. https://doi.org/10.1002/dad2.12031.
留言 (0)